The Hair Loss Pill Hits Its Biggest Test in 2026: What VDPHL01's Phase 3 Readout Means for Patients

On October 18, Veradermics announced it would present results from Part A of Study '304', a randomized, double-blind, placebo-controlled Phase 3 trial of VDPHL01 in more than 500 men with mild-to-moderate pattern hair loss, on an investor call the morning of October 19. The trial is "registration-directed," meaning it is designed to support an application for FDA approval.

This is the second of two large male trials. The first, Study '302', reported its results in April 2026, and those numbers are why dermatologists have been paying close attention. If '304' confirms them, VDPHL01 would be positioned to become the first FDA-approved non-hormonal oral treatment for pattern hair loss — and the first genuinely new approved option since finasteride arrived in the late 1990s.

Study '302' enrolled 519 men with mild-to-moderate pattern hair loss and compared two doses of VDPHL01 — 8.5 mg once daily and 8.5 mg twice daily — against placebo over six months. According to the company's published topline results, men on the once-daily dose gained an average of 30.3 new non-vellus hairs per square centimeter in the target area, and men on the twice-daily dose gained 33.0 — versus just 7.3 for placebo.

The patient-experience numbers were arguably more striking. By month six, 79.3% of once-daily patients and 86.0% of twice-daily patients reported improved hair coverage, compared with 35.6% on placebo. Investigators rated 72.0% (once daily) and 84.4% (twice daily) of treated men as having improved coverage. And the improvement showed up early: the difference from placebo was statistically significant by month two, the earliest time point measured.

Just as important for a minoxidil product, the safety profile looked clean. Overall side effect rates were similar to placebo, fewer patients on the drug dropped out than on placebo, and the trial recorded no treatment-related serious adverse events and no cardiac adverse events of special interest — findings also highlighted in coverage of the trial earlier this year.

Low-dose oral minoxidil is already one of the fastest-growing hair loss treatments in the US — but every tablet of it today is prescribed off-label. Minoxidil pills were originally approved decades ago as a blood pressure medication, and the immediate-release tablets dermatologists repurpose carry cardiovascular warnings and can cause side effects like lightheadedness, palpitations, and fluid retention.

VDPHL01 is an extended-release formulation designed to smooth out the peaks in blood levels that drive those effects — the goal, in the company's words, is to optimize oral minoxidil for hair growth while minimizing side effects and cardiac risk. If it is approved, patients and providers would for the first time have an oral minoxidil with FDA-reviewed dosing, efficacy, and safety data specifically in pattern hair loss, rather than borrowing a blood pressure drug and adjusting on experience.

That doesn't make today's off-label option unreasonable — many dermatologists and telehealth providers prescribe low-dose oral minoxidil safely with appropriate screening. But it does mean the evidence base is about to get much stronger, one way or the other.

The two FDA-approved mainstays remain finasteride and topical minoxidil, and they are not going anywhere. Finasteride attacks the hormonal driver of male pattern hair loss (DHT) and remains the best-studied option for stopping progression. Topical minoxidil is approved over the counter and works for many men who use it consistently — though consistency is exactly where many people struggle, and side effects like scalp irritation lead some to quit.

A once-daily pill that grew roughly 30 new hairs per square centimeter in six months, with placebo-like tolerability, would slot in as an attractive option for men who can't or don't want to take a hormonal medication, or who have struggled with topical routines. Keep in mind the caveats: Study '302' tested VDPHL01 against placebo, not head-to-head against finasteride or topical minoxidil, and VDPHL01 remains investigational — it is not FDA approved today, and no approval timeline has been announced. Combination approaches (for example, finasteride plus minoxidil, or adding dutasteride in resistant cases) will still be individualized decisions made with a licensed provider.

Three things will determine how quickly this translates into something you can actually be prescribed. First, whether the '304' results released today confirm the '302' efficacy and safety picture. Second, whether Veradermics moves to file for FDA approval — the company has not yet announced a filing date, and a women's trial (Study '306') is still recruiting. Third, pricing and access: a branded, FDA-approved tablet will almost certainly cost more than today's generic off-label minoxidil, and insurers rarely cover hair loss treatment, so the real-world comparison will come down to out-of-pocket cost.

In the meantime, nothing about this news changes the most important variable in treating hair loss: starting early. Every treatment that exists works far better at preserving hair than regrowing it after follicles have miniaturized for years.

If you're noticing thinning now, you don't need to wait for a new drug to act. JoeyMed's licensed providers can evaluate your hair loss online and, when appropriate, prescribe today's proven options — finasteride, minoxidil, and dutasteride for resistant cases — with discreet home delivery and ongoing follow-up. A provider can also help you decide whether current treatments fit your health history, screen for contraindications, and set realistic expectations for what results look like at 3, 6, and 12 months.

Explore your options at JoeyMed Hair Growth and start a consultation from home — and when new treatments like VDPHL01 clear the FDA, we'll break down what they mean for your plan, just like this.

This article is for general information and is not medical advice. Treatment decisions should always be made with a licensed healthcare provider.